Using PC-3 and DU145 human prostate cancer cells, Fang et al. [29] have demonstrated that luteolin inhibits the IGF-I-induced activation of IGF-IR and AKT as well as the downstream targets of AKT, p70S6K1, GSK-3β, and FKHR/FKHRL1. Here, FOXO3 is linked to prostate carcinoma.